The case for & against
Bull & Bear analysis
Bearish
Evergen Ltd. (NASDAQ: EVGN) is a biotechnology company focused on leveraging artificial intelligence to innovate in drug discovery and agricultural chemicals. Positioned within competitive pharma and ag-chem markets, Evergen utilizes its proprietary Campus AI platform to enhance the efficiency and efficacy of small-molecule design and crop protection solutions.
Bull says
- ↑Partnership with Google enhances Campus AI platform for molecule design.
- ↑OpEx fell from $11.1M to $7.7M YOY; R&D costs cut to $1.8M.
- ↑Targeting $780B pharma and crop‐protection markets for long‐term revenue.
- ↑Three new biotech/agri collaborations in Q1 could drive future income.
- ↑Strong liquidity and stable cash runway support ongoing R&D investments.
- ↑Low share volatility and modest interest‐rate sensitivity suggest stability.
Bear says
- ↓Q1 revenue collapsed 87% YoY to $0.3M, driven by Castera seed slump.
- ↓Q1 net loss rose to $5.9M from $3.0M, fueled by lower sales.
- ↓Cash burn of $2.8M in Q1 and $13.1M cash raise runway concerns.
- ↓Bayer deal termination highlights risks to innovation pipeline continuity.
- ↓Negative earnings yield and weak profitability signal poor return potential.
- ↓High short interest and small scale warn of investor skepticism.
Earnings Call · Q1 2025 · Mgmt. Guidance
Updated 05-21-2026neutral
Transcript signals
Bull points
- In the first quarter of 2025, total revenues were approximately $2.4 million, compared to approximately $4.2 million in the first quarter of 2024, driven primarily by an increase in seed sales by Castera.
- In the first quarter of 2025, total R&D expenses were approximately $3.2 million compared to approximately $4.8 million in the first quarter of 2024, indicating a decrease mainly due to reduced R&D activity, demonstrating effective cost management.
- The phase one clinical study of BMC-128 is progressing with new data showing early signs of effectiveness through immune activations observed within 14 days of treatment.
Bear points
- In the first quarter of 2025, total operating expenses net were approximately $5 million, compared to approximately $8 million in the first quarter of 2024, indicating a significant ongoing operational challenge.
- It is important to highlight that additional funding is necessary to advance to phase two of the clinical study regarding BMC-128, highlighting potential financial strain on Biomica in the near future.
- in order to proceed to phase two, of the clinical study for BMC128, additional funding will be required.
Read full transcript analysis ›